带状疱疹mRNA疫苗LVRNA015在动物模型中免疫应答优于已上市疫苗且安全性良好
研究开发了含序列优化mRNA编码修饰糖蛋白E的带状疱疹mRNA疫苗LVRNA015,在BALB/c小鼠中诱导持续超过9个月的体液和细胞免疫应答,中和抗体水平和抗原特异性T细胞细胞因子产生显著高于Shingrix®,大鼠急性与重复给药毒性试验及豚鼠主动全身过敏试验未观察到显著安全性信号。
要点
- LVRNA015在BALB/c小鼠中诱导的体液和细胞免疫应答强度显著高于减毒活VZV。
- LVRNA015诱导的中和抗体水平和抗原特异性T细胞细胞因子产生显著高于Shingrix®。
- 大鼠急性和重复给药毒性试验及豚鼠主动全身过敏试验未观察到显著安全性信号。
核心结论
- LVRNA015在动物模型中诱导的免疫应答优于已上市疫苗Shingrix®且安全性良好,支持推进临床研究。
研究设计与样本
- 临床前动物研究:在BALB/c小鼠中评价免疫原性,在大鼠中进行急性和重复给药毒性试验,在豚鼠中进行主动全身过敏试验。
主要发现
- LVRNA015在BALB/c小鼠中诱导稳健的体液和细胞免疫应答持续超过9个月。
- LVRNA015诱导的免疫应答强度显著高于减毒活VZV。
- LVRNA015接种小鼠的中和抗体水平和抗原特异性T细胞细胞因子产生显著高于Shingrix®接种小鼠。
- 最终免疫后7个月可检测到记忆T细胞,提示诱导持久免疫记忆应答。
- 大鼠给药后体重及血液学和生化标志物未见显著改变,豚鼠主动全身过敏试验未见过敏反应。
临床怎么用
- 目前仅为动物模型证据,尚不能直接用于临床决策,需等待临床试验验证。
局限性
- 研究仅在动物模型中进行,尚未在人体中验证免疫原性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herpes zoster, a painful rash that is commonly known as shingles, occurs when the varicella-zoster virus is reactivated from its latent state in neurons. The condition is more frequent among older or immunocompromised individuals. Although the licensed vaccine Shingrix® has demonstrated high efficacy against herpes zoster, its undesired reactogenicity and escalating global demand have necessitated the development of improved or novel VZV vaccines. In the present research, we developed a VZV mRNA vaccine candidate, LVRNA015, that contains sequence-optimized mRNA encoding modified glycoprotein E encapsulated in an ionizable lipid nanoparticle. Our results demonstrated that LVRNA015 exhibited robust humoral and cellular immune responses for over 9 months in BALB/c mice. The magnitude of these responses was significantly higher than that observed with live attenuated VZV. Notably, mice vaccinated with LVRNA015 exhibited significantly higher neutralizing antibody levels and antigen-specific T-cell cytokine production in comparison with those receiving Shingrix®. Additionally, LVRNA015 induced a long-lasting immunological memory response, as evidenced by detection of memory T cells at 7 months after the final immunization. To evaluate vaccine safety, acute and repeat-dose toxicity studies were performed in rats; no significant alterations in body weight or in hematological and biochemical markers were observed following LVRNA015 administration. Active systemic anaphylaxis tests in guinea pigs showed no hypersensitivity in LVRNA015-treated animals. These findings support the further advancement of LVRNA015 to clinical studies as a promising shingles vaccine.
引用
- Chen Y, Liu Q, Wang C, et al. Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models. Vaccine. 2025. PMID: 41418604. doi:10.1016/j.vaccine.2025.128136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。